New products from Eli Lilly
Eli Lilly & Co. (LLY) has launched various products under different franchises. A few of the company’s new products include Portrazza, Cyramza, Basaglar, Jardiance, Taltz, and Trulicity. In this article, we’ll discuss these products and their performance profiles during the last quarter.
Basaglar is an insulin glargine injection to control blood sugar levels in patients with type 1 and type 2 diabetes. Basaglar launched in the US market on December 15, 2016. In 4Q16, Eli Lilly (LLY) reported Basaglar sales of $40 million from Japan and several European markets.
Cyramza is an oncology drug used in combination with other drugs for the treatment of metastatic NSCLC, advanced gastric cancer, and metastatic colorectal cancer.
In 4Q16, Cyramza’s sales increased over 51% to $177 million. This increase was due to the increased demand in Japan and its European markets for the treatment of metastatic NSCLC and metastatic colorectal cancer.
Eli Lilly’s Jardiance is used to lower blood sugar levels in patients with type 2 diabetes. Jardiance is a part of the Boehringer Ingelheim and Eli Lilly diabetes alliance. In 4Q16, the drug’s revenues totaled $76 million compared to $15 million for 4Q15, mainly driven by increased sales in the US markets.
Approved by the FDA in November 2015, Portrazza is used for the treatment of metastatic squamous non-small cell lung cancer (or NSCLC). Portrazza reported sales of ~$3.8 million in 4Q16.
Other drugs in the oncology field include Pfizer’s (PFE) Inlyta and Sutent, Bristol-Myers Squibb’s (BMY) Opdivo, Merck & Co.’s (MRK) Keytruda, GlaxoSmithKline’s (GSK) Mekinist and Tafinlar, and Roche’s (RHHBY) Zelboraf.
Eli Lilly & Co. (LLY) launched Taltz in the US markets in April 2016, followed by its launch in the European markets in July 2016. In 4Q16, Taltz’s revenues totaled $61 million, which was dominated by its US sales of $59 million.
Trulicity is used to improve blood sugar levels in patients with type 2 diabetes. In 4Q16, Trulicity reported sales of $337.0 million compared to $112.5 million in 4Q15.
Lartruvo is used in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The drug was launched in the US and European markets in 4Q16 and reported revenues of $11.9 million during the quarter.